Bairen Medical announces strong 2024 preliminary results

Beijing Bairen Medical Technology Co., Ltd. (SSE:688198) announced its preliminary financial results for 2024, showcasing robust growth. Total operating income surged by 35.67% year-over-year to RMB 502.83 million, driven by successful product launches and expanded market penetration. Net profit attributable to shareholders increased by 26.26% to RMB 145.46 million. The company's R&D investments also grew significantly, up 56.14% and accounting for 30.68% of operating revenue. Total assets reached RMB 1,452.96 million, a 9.49% increase, while shareholders' equity attributable to the parent company rose by 5.70% to RMB 1,262.75 million. Bairen Medical cautioned investors that these figures are preliminary and subject to change pending final audit.